JSSH
NBIX icon

J. Safra Sarasin Holding’s Neurocrine Biosciences NBIX Stock Holding History

J. Safra Sarasin Holding’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
+6,899
New +$1.02M 0.02% 356
2026
Q1 		– Sell
-3,966
Closed -$562K – 573
2025
Q4 		$562K Sell
3,966
-2,295
-37% -$332K 0.01% 387
2025
Q3 		$879K Buy
+6,261
New +$848K 0.01% 329

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Safra Sarasin Holding's NBIX Position: Q2 2026 in Review

J. Safra Sarasin Holding opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 6,899 shares worth $1.16M. The stake represents 0.02% of the portfolio and ranks #356 among its holdings. This is a return to the name: J. Safra Sarasin Holding previously reported a position in NBIX as recently as Q4 2025.

J. Safra Sarasin Holding first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • J. Safra Sarasin Holding held 6,899 shares of Neurocrine Biosciences worth $1.16M as of Q2 2026.
  • Neurocrine Biosciences was a new J. Safra Sarasin Holding position in Q2 2026.
  • Neurocrine Biosciences made up 0.02% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #356 holding.
  • J. Safra Sarasin Holding first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.